Placebo News and Research

RSS

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers report positive results from the first placebo-controlled long-term trial of anifrolumab - a human monoclonal antibody that targets the type I IFN receptor - in patients with lupus.

14 Nov 2022

Genicular nerve blocks provide short term pain relief for patients with knee osteoarthritis

Results from a recent clinical trial published by Wiley in Arthritis & Rheumatology demonstrate that patients with knee osteoarthritis experience short term pain relief from genicular nerve blocks - or locally injected anesthetics that block nerves around the knee joint.

13 Nov 2022

Study evaluates transcutaneous vagus nerve stimulation as treatment for long COVID-chronic fatigue

In a recent study posted to the medRxiv* server, researchers evaluated non-invasive transcutaneous vagus nerve stimulation [tVNS] as a treatment for long COVID-related chronic fatigue syndrome (CFS).

10 Nov 2022

Does fenofibrate improve clinical outcomes in patients with COVID-19?

Researchers assessed the effect of fenofibrate on acute COVID-19.

9 Nov 2022

Study: Fenofibrate not a useful strategy for decreasing COVID-19 severity

After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant effect on COVID-19 outcomes in a multicenter international randomized clinical trial led by Penn Medicine scientists.

8 Nov 2022

Long-term administration of IV iron benefits adults with heart failure and iron deficiency

Long-term treatment with iron administered intravenously improved symptoms and reduced recurrent hospitalizations among people with heart failure and iron deficiency, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2022.

7 Nov 2022

Administering steroids during heart surgery does not improve post-operative outcomes in infants

The largest clinical trial ever conducted in infants younger than age 1 undergoing heart surgery with cardiopulmonary bypass found that administering steroids during surgery did not improve post-operative outcomes compared to placebo, according to preliminary late-breaking research to be presented at the American Heart Association's Scientific Sessions 2022.

7 Nov 2022

SGLT-2 inhibitors reduce cardiovascular risk among patients with chronic kidney disease

SGLT-2 inhibitors, a type of diabetes medicine, decreased cardiovascular risk among adults with chronic kidney disease, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2022.

7 Nov 2022

Dietary supplements taken for 'heart health' unlikely to offer meaningful impact on cholesterol levels

Six widely used dietary supplements promoted for improving heart health did not effectively lower LDL or "bad" cholesterol in comparison to a common low-dose statin medication or placebo, according to late breaking science results presented today at the American Heart Association's Scientific Sessions 2022.

7 Nov 2022

New medication lowers triglyceride levels, yet does not decrease cardiovascular risk in people with Type 2 diabetes

A new medication, pemafibrate, lowered triglyceride levels among adults with Type 2 diabetes yet did not decrease their cardiovascular risk, according to late-breaking science research presented today at the American Heart Association's Scientific Sessions 2022.

7 Nov 2022

Rosuvastatin vastly superior to six common heart health supplements

Six widely used dietary supplements often advertised to promote heart health are actually ineffective at lowering cholesterol levels.

7 Nov 2022

New study provides more clarity about giving steroids during pediatric open-heart surgery

For more than four decades, doctors have been split on whether giving steroids during a pediatric open-heart surgery could be helpful for post-operative recovery.

6 Nov 2022

Novel drug lowers triglycerides, does not reduce cardiovascular events

Levels of triglycerides are routinely measured as part of a preventive cardiology work-up and lowering triglycerides with several classes of drugs is common medical practice.

6 Nov 2022

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Moderna's COVID-19 vaccine is safe and effective in children 6 months to 5 years of age, a clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found.

4 Nov 2022

H pylori eradication protects against aspirin-associated peptic ulcer bleeding

A new study, led by experts at the University of Nottingham found that the risk of stomach bleeding caused by using aspirin long-term, can be reduced with a short course of antibiotics, potentially improving the safety of aspirin when used to prevent heart attacks, strokes and possibly some cancers.

4 Nov 2022

Fermented dairy products can improve gut mucosal immunity

In a recent study published in the journal Immunology Letters, researchers assessed the role of fermented dairy products and dairy starters in modulating gut mucosal immunity.

3 Nov 2022

Weekly weight loss drug reduces BMI in teens

Researchers report that a weekly dose of semaglutide led to a significant BMI reduction in adolescents.

3 Nov 2022

Study explores the potential use of anti-thymic stromal lymphopoietin monoclonal antibody as an adjuvant in allergic immunotherapy

A new study investigated the impact of a monoclonal anti-thymic stromal lymphopoietin (TSLP) antibody on subcutaneous allergen immunotherapy (SCIT) efficacy among patients with allergic rhinitis.

3 Nov 2022

The maternal RSV vaccine from Pfizer protects newborns against severe illness

Pfizer announced its maternal vaccine against RSV to be almost 82% effective in protecting infants for the first 90 days of life against severe illness.

1 Nov 2022

Cohort study determines how often COVID-19 symptoms recurred

Researchers at University of California San Diego School of Medicine, with colleagues from the ACTIV-2 trial, part of the U.S. government's response to COVID-19, investigated whether symptoms of COVID-19 recurred following a two-day symptom-free period in persons who did not receive any treatment for the disease.

1 Nov 2022

Placebo News and Research

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

Genicular nerve blocks provide short term pain relief for patients with knee osteoarthritis

Study evaluates transcutaneous vagus nerve stimulation as treatment for long COVID-chronic fatigue

Does fenofibrate improve clinical outcomes in patients with COVID-19?

Study: Fenofibrate not a useful strategy for decreasing COVID-19 severity

Long-term administration of IV iron benefits adults with heart failure and iron deficiency

Administering steroids during heart surgery does not improve post-operative outcomes in infants

SGLT-2 inhibitors reduce cardiovascular risk among patients with chronic kidney disease

Dietary supplements taken for 'heart health' unlikely to offer meaningful impact on cholesterol levels

New medication lowers triglyceride levels, yet does not decrease cardiovascular risk in people with Type 2 diabetes

Rosuvastatin vastly superior to six common heart health supplements

New study provides more clarity about giving steroids during pediatric open-heart surgery

Novel drug lowers triglycerides, does not reduce cardiovascular events

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

H pylori eradication protects against aspirin-associated peptic ulcer bleeding

Fermented dairy products can improve gut mucosal immunity

Weekly weight loss drug reduces BMI in teens

Study explores the potential use of anti-thymic stromal lymphopoietin monoclonal antibody as an adjuvant in allergic immunotherapy

The maternal RSV vaccine from Pfizer protects newborns against severe illness

Cohort study determines how often COVID-19 symptoms recurred

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News